Differences in patient characteristics, disease-modifying treatment utilization, and relapse by race/ethnicity in Texas medicaid patients with multiple sclerosis

被引：0
|
作者：
Richards, K. M. [1 ]
Lawson, K. A. [1 ]
Nazareth, T. [2 ]
Yu, T. -C. [2 ]
Ko, J. J. [2 ]
Burton, E. [3 ]
Sasane, R. [2 ]
机构：
[1] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA
[2] Novartis Pharmaceut, Hlth Econ & Outcomes Res, E Hanover, NJ USA
[3] Novartis Pharmaceut, US Med Affairs, E Hanover, NJ USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P658
引用
收藏
页码：322 / 323
页数：2
相关论文
共 50 条
  • [31] FIRST USE OF DISEASE-MODIFYING DRUGS IN PATIENTS WITH MULTIPLE SCLEROSIS
    Meletiche, D. M.
    Kozma, C.
    Dickson, M.
    VALUE IN HEALTH, 2009, 12 (03) : A193 - A193
  • [32] Prescribing disease-modifying treatments for older patients with multiple sclerosis
    Lopez Ruiz, Rocio
    Eichau Madueno, Sara
    Cortes Zujar, Beatriz
    Canaveral, Marta
    Arzalluz, Joaquin
    Ben Yelun Insenser, Miriam
    Dotor, Julio
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1086 - 1086
  • [33] Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis
    Hincapie, Ana L.
    Penm, Jonathan
    Burns, Craig F.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (08): : 822 - 830
  • [34] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Simona Lattanzi
    Maura Danni
    Ruja Taffi
    Raffaella Cerqua
    Giulia Carlini
    Alessandra Pulcini
    Leandro Provinciali
    Mauro Silvestrini
    Journal of Neurology, 2017, 264 : 2325 - 2329
  • [35] Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies
    Elena Grebenciucova
    Amy Pruitt
    Current Neurology and Neuroscience Reports, 2017, 17
  • [36] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Lattanzi, Simona
    Danni, Maura
    Taffi, Ruja
    Cerqua, Raffaella
    Carlini, Giulia
    Pulcini, Alessandra
    Provinciali, Leandro
    Silvestrini, Mauro
    JOURNAL OF NEUROLOGY, 2017, 264 (11) : 2325 - 2329
  • [37] Vaccinations in multiple sclerosis patients receiving disease-modifying drugs
    Otero-Romero, Susana
    Ascherio, Alberto
    Lebrun-Frenay, Christine
    CURRENT OPINION IN NEUROLOGY, 2021, 34 (03) : 322 - 328
  • [38] Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis
    Alosaimi, Fahad D.
    AlMulhem, Alaa
    AlShalan, Hanan
    Alqazlan, Mohammad
    Aldaif, Abdulgader
    Kowgier, Matthew
    Balasundaram, Janooshsheya
    Sockalingam, Sanjeev
    PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 513 - 518
  • [39] Treatment Patterns Among Patients With Multiple Sclerosis Newly Initiating Disease-Modifying Therapy
    Freeman, Leorah
    Mehta, Rina
    Tian, Marc
    Pelletier, Corey
    NEUROLOGY, 2020, 94 (15)
  • [40] Time to First Treatment with Disease-Modifying Drugs in Newly Diagnosed Patients with Multiple Sclerosis
    Meletiche, Dennis M.
    Kozma, Chris
    Dickson, Michael
    NEUROLOGY, 2009, 72 (11) : A315 - A315
12345